Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $88.6 million.

  • Ironwood Pharmaceuticals' Cash & Equivalents rose 59.17% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year increase of 59.17%. This contributed to the annual value of $88.6 million for FY2024, which is 3.90% down from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Cash & Equivalents stood at $88.6 million, which was down 3.90% from $92.2 million recorded in FY2023.
  • Ironwood Pharmaceuticals' 5-year Cash & Equivalents high stood at $656.2 million for FY2022, and its period low was $88.6 million during FY2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Cash & Equivalents had a median value of $92.2 million in 2023 and averaged $279.0 million.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Cash & Equivalents soared by 104.81% in 2020, and later tumbled by 85.96% in 2023.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Cash & Equivalents stood at $362.6 million in 2020, then spiked by 71.04% to $620.1 million in 2021, then increased by 5.82% to $656.2 million in 2022, then slumped by 85.96% to $92.2 million in 2023, then fell by 3.90% to $88.6 million in 2024.